HSC-T6大鼠肝星形細胞（附
- 公司名稱 上海富雨生物科技有限公司
- 品牌
- 型號
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時間 2025/2/11 18:10:30
- 訪問次數(shù) 78
聯(lián)系方式：陳壽彬18956075901 查看聯(lián)系方式
聯(lián)系我們時請說明是化工儀器網(wǎng)上看到的信息，謝謝!
大鼠肝星形細胞HSC-T6
| 屬 | 大鼠 |
| 別稱 | HSCT6 |
| 組織來源 | 肝臟 |
| 疾病 | 轉(zhuǎn)化細胞系 |
| 傳代比例/細胞消化 | 1:2傳代,消化1-2分鐘 |
| 培養(yǎng)基配置 | DMEM養(yǎng)基；10%胎牛血清；1%雙抗 |
| 形態(tài) | 上皮細胞樣 |
| 生長特征 | 貼壁生長 |
| 倍增時間 | 每周 2 至 3 次 |
| 培養(yǎng)條件 | 氣相：空氣，95%；二氧化碳，5%。 溫度：37攝氏度，培養(yǎng)箱濕度為70%-80%。 |
| 凍存條件 | 凍存液 ：90%FBS ，DMSO 10%, 或使用非程序凍存液 ：貨號JY-H040 |
| 保藏機構(gòu) | Millipore; SCC069 |
| 產(chǎn)品使用 | 于科學研究 ，不可作為動物或人類疾病的治療產(chǎn)品使用。 |
Introduction: Blunt traumatic aortic injury (TAI) is a critical condition and a leading cause of mortality in trauma patients, often resulting from high-speed accidents. Thoracic endovascular aortic repair (TEVAR) has developed into the preferred therapeutic approach due to its minimally invasive nature and promising outcomes. This study evaluates the safety and efficacy of TEVAR for managing TAI over a 10-year period at a Level-1 trauma center.
Methods: A retrospective analysis was conducted on 19 patients with acute TAI treated with TEVAR between 2012 and 2022 at the University Hospital Zurich. Data were collected from digital records and analyzed according to the Fillinger TEVAR reporting framework. Outcomes included technical success, perioperative complications, and long-term graft durability.
采購中心
化工儀器網(wǎng)